Hepatitis B virus: A comprehensive strategy for eliminating transmission in the United States

Journal of Long-Term Effects of Medical Implants

Volumn 13, Issue 2, 2003, Pages 117-125

  Edlich, Richard F ^a,c   Diallo, Alfa O ^b   Buchanan, Leslie ^a   Martin, Marcus L ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c NONE   (United States)

Author keywords

Cirrhosis; Healthcare workers; Hepatitis; Hepatitis B immune globulin; Hepatitis B vaccine; Hepatitis B virus; Hepatitis B virus core antigen; Hepatitis B virus e antigen; Hepatitis B virus surface antigen; High risk groups; Homosexuals; Infants; Liver cancer

Indexed keywords

ANTIGENS; DISEASES; VACCINES; VIRUSES;

VACCINATION;

IMPLANTS (SURGICAL);

BAYHEP B; HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; HEPATITIS B ANTIBODY; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIGEN; RECOMBINANT HEPATITIS B VACCINE; TWINREX;

ANAPHYLAXIS; ANGIONEUROTIC EDEMA; BODY FLUID; EPIDEMIC; HEPATITIS B VIRUS; HOSPITAL PERSONNEL; HUMAN; IMMUNIZATION; INFECTION PREVENTION; INFECTION RISK; INJECTION PAIN; NONHUMAN; OCCUPATIONAL EXPOSURE; REVIEW; SIDE EFFECT; UNITED STATES; URTICARIA; VIRUS TRANSMISSION;

ADOLESCENT; ADULT; CHILD; HEPATITIS B; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HUMANS; INFANT, NEWBORN; MALE; RISK FACTORS; UNITED STATES;

EID: 0038665171     PISSN: 10506934     EISSN: None     Source Type: Journal    
DOI: 10.1615/JLongTermEffMedImplants.v13.i2.60     Document Type: Review

References (32)

1. Purcell RH. The discovery of hepatitis viruses. Gastroenterology 1993; 104:955-963.
2. Hadler SC. Global impact of hepatitis B virus infection. Changing patterns. In: Hollinger FB, Lemon SM, Margolis HS, editors. Viral Hepatitis and Liver Disease. Baltimore: Williams & Wilkins, 1991:14-20.
3. Long J, Kyllonen K. Adult vaccination: a short review. Cleve Clin J Med 1997; 64:311-317.
4. François G, Halluer J, Van Damme P. Hepatitis B vaccination: how to reach high risk groups. Vaccine 2002; 21:1-4.
5. Viral Hepatitis Prevention Board. Hepatitis B control and prevention in mobile populations. Viral Hepatit 2000; 8:1-16.
6. Lee WM. Medical progress: hepatitis B virus infection. New Engl J Med 1997; 337:1733-1745.
7. Harpaz R, Von Seidlein L, Aberhoff FM, Tormey MP, Sinha SD, Kotsopoulou K, Lambert SB, Robertson BH, Cherry JD, Shapiro CN. Transmission of hepatitis B virus to multiple patients from a surgeon without evidence of inadequate infection control. New Engl J Med 1996; 334:549-554.
8. Incident Investigation Team. Transmission of hepatitis B to patients from four infected surgeons without hepatitis B e antigen. New Engl J Med 1997; 336:178-184.
9. Centers for Disease Control and Prevention. Guidelines for prevention of transmission of human immunodeficiency virus and hepatitis B virus to health-care and public-safety workers A response to P.L. 100-607 The Health Omnibus Programs Extension Act of 1988. MMWR 1989; 38 (S-6):3-37.
10. Lee WM. Medical progress: hepatitis B virus infection. N Engl J Med 1997; 337 (24):1733-1745.
11. Centers for Disease Control and Prevention. Hepatitis B vaccination - United States, 1982-2002. MMWR 2002; 51:549-552.
12. Armstrong GL, Mast EE, Wojczynski M, Margolis HS. Childhood hepatitis B virus infections in the United States before hepatitis B immunization. Pediatrics 2001; 108:1123-1128.
13. Centers for Disease Control and Prevention. Safety of therapeutic immune globulin preparations with respect to transmission of human T-lymphotropic virus type III/ lymphadenopathy-assoicated virus infection. MMWR 1986; 35:231-233.
14. Ellis EF, Henney CS. Adverse reactions following administration of human gamma globulin. J Allergy 1969; 43:45-54.
15. Centers for Disease Control and Prevention. Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination: recommendation of the Immunization Practices Advisory Committee (ACIP). MMWR 1991; 40 (RR-13):1-19.
16. Centers for Disease Control and Prevention. Inactivated hepatitis B vaccine. MMWR 1982; 31:317-318.
17. Chiarello LA, Cardo DM. Preventing transmission of hepatitis B virus from surgeons to patients. Infect Control Hosp Epidemiol 2002; 23:301-302.
18. rd, Edwards JR, Srivastava PU, Culver DH, et al. Serosurvey of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus infection among hospital-based surgeons. Serosurvey Study Group. J Am Coll Surg 1995; 180:16-24.
19. Shapiro CN, Tokars JI, Chamberland ME. Use of hepatitis B vaccine and infection with hepatitis B and C among orthopaedic surgeons. J Bone Joint Surg Am 1996; 78:1791-1800.
20. Thomas DL, Gruninger SE, Sieu C, Joy ED, Quinn TC. Occupational risk of hepatitis C infections among general dentists and oral surgeons in North America. Am J Med 1996; 100:41-45.
21. Advisory Committee on Immunization Practices. Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination: recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR 1991; 40 (no. RR-13):1-19.
22. Centers for Disease Control and Prevention. Hepatitis B vaccination of adolescents - California, Louisiana and Oregon, 1992-1994. MMWR 1994; 43:605-609.
23. Francis DP. The public's health unprotected. Reversing a decade of underutilization of hepatitis B vaccine. JAMA 1995; 274:1242-1243.
24. Beasley RP, Hwang L-Y. Epidemiology of hepatocellular carcinoma. In: Vyas GN, Dienstag JL, Hoofnagle JH, editors. Viral Hepatitis and Liver Disease. New York: Grune & Stratton, 1984:209-224.
25. Beasley RP, Hwang L-Y. Postnatal infectivity of hepatitis B surface antigen-carrier mothers. J Infect Dis 1983; 147:185-190.
26. Beasley RP, Hwang L-Y, Stevens CE, Lin CC, Hsieh FJ, Wang KY, Sun TS, Szmuness W. Efficacy of hepatitis B immune globulin for prevention of perinatal transmission of the hepatitis B virus carrier state: final report of a randomized double-blind, placebo-controlled trial. Hepatology 1983; 3:135-141.
27. Centers for Disease Control and Prevention. Hepatitis B vaccination of adolescents - California, Louisiana, and Oregon, 1992-1994. MMWR 1994; 43(33):605-609.
28. Seaworth B, Drucker J, Starling J, Drucker R, Stevens C, Hamilton J. Hepatitis B vaccines in patients with chronic renal failure before dialysis. J Infect Dis 1988; 157:332-337.
29. Moyer LA, Alter MJ, Favero MS. Hemodialysis-associate hepatitis B: revised recommendations for serologic screening. Semin Dialysis 1990; 3:201-204.
30. Khan A, Goldstein S, Williams I, Bell B, Mast E. Opportunites for hepatitis B prevention in correctional facilities and sexually transmitted disease treatment settings. In: proceedings of the 10th International Symposium on Viral Hepatitis and Liver Disease. Atlanta, GA: US International Medical Press. 2000:21.
31. Centers for Disease Control and Prevention. Recommendation of the Immunization Practices Advisory Committee (ACIP) MMWR 1991; 40(RR-12):1-52.
32. Pisu M, Meltzer MI, Lyerla R. Cost-effectiveness of hepatitis B vaccination of prison inmates. Vaccine 2002; 21:312-321.